Cerevel Therapeutics Holdings, Inc.
CERE
|
$42.15
0.02%
0.02%
810K
|
Finance
(0.0% 1d) (-0.1% 1m) (55.6% 1y) (0.8% 2d) (1.6% 3d) (1.2% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 7,653,448,716
https://www.cerevel.com
Sec Filling | Patents | 122 employees
(US) Cerevel Therapeutics Holdings, Inc. operates as an investment holding company. The company is headquartered in Boston, MA.
schizophrenia
add to watch list Paper trade email alert is off
Press-releases
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law Firm
Published: 2024-01-24 (Crawled : 13:30) - prnewswire.com
WAVD | $2.02 -5.39% -5.69% 17K
|
Information
|
| O: -6.25%
H: 9.33%
C: 7.33%
NS 3 d | $22.11 2.13% 0.0% 560K
|
Distribution Services
|
| O: -0.62%
H: 2.53%
C: -0.14%
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.43%
H: 0.0%
C: -0.76%
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.78%
H: 4.49%
C: 1.55%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.09%
H: 3.38%
C: 3.18%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.54%
H: 3.6%
C: 2.42%
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: -0.14%
H: 0.19%
C: -0.31%
conference abbvie
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CERE, WAVD, ICVX, EAR
Published: 2023-12-28 (Crawled : 02:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.75%
H: 0.24%
C: -0.32%
EAR | $2.57 7.78% 200K
|
Health Technology
|
| O: 0.78%
H: 0.78%
C: 0.39%
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.52%
H: 0.82%
C: -0.19%
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Published: 2023-12-09 (Crawled : 20:20) - prnewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
| Email alert
Add to watchlist
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $290.38 3.83% 220
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody antibody treatment response
CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics
Published: 2023-12-07 (Crawled : 05:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 12.02%
H: 0.92%
C: -0.58%
acquisition therapeutics potential
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Published: 2023-12-06 (Crawled : 22:00) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.44%
H: 1.01%
C: 0.74%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.31%
H: 0.38%
C: 0.38%
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 12.02%
H: 0.92%
C: -0.58%
abbvie pipeline acquire therapeutics
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.24%
H: 5.19%
C: 1.2%
disease parkinson’s therapeutics
Cerevel Therapeutics to Present at Upcoming Investor Conferences
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 1.04%
H: 0.0%
C: -3.2%
therapeutics
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Published: 2023-11-01 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 3.34%
H: 4.0%
C: 3.72%
business therapeutics financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
COMP | $3.24 -0.61% 6.48% 2.4M
|
LYT | $4.22 4.72% 5.62% 1.4M
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10